On 3/27/24, Lixte Bio (LIXT) put out a PR with an all-caps headline stating “NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND,CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES”.

However, this publication wasn’t new. LIXT stated “announced today (3/27/24) publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled “Paradoxical activation of oncogenic signaling as a cancer treatment strategy”. See the publication here. Below is a screenshot:

However, this exact same publication, word for word, was published on 2/7/23, over a year ago here. Screenshot below:

As shown on that same page under “Info/History” that paper was published over a year ago, as shown below:

LIXT also mentioned in yesterday’s PR: This “tumor suppressive drug resistance” stems from the unique features of LB-100.

And they used the exact same wording in their PR on 2/7/23. Screenshot below: